We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRGO:NYSEPerrigo Company plc Analysis

Data as of 2026-08-23 - not real-time

$14.25

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Perrigo Company plc is priced at $14.25, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 39.4%. RSI sits at 71.6, which reads as overbought, and MACD momentum is bullish. Watch $10.01 as support and $14.26 as the nearer resistance level.
Multiples put this in undervalued territory: 5.9 times earnings against the sector's 31.1. Sell-side targets cluster 15.8% above the current quote. Revenue is contracting at 3.2% on a -41.9% profit margin. The 8.14% dividend yield looks stretched against payout coverage.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 77.8%, a beta of 1.05 and a maximum drawdown of 62.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.

Top Market Events

Perrigo Co PLC PRGO navigates a challenging quarter with strategic wins in infant formula and innovation, despite a 3.Perrigo Company plc NYSE: PRGO , a leading provider of consumer self-care products, today announced that it plans to...14dPerrigo Q2 Earnings Call HighlightsPerrigo NYSE:PRGO reported second-quarter 2026 results that exceeded its internal...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • RSI at 71.6 signals overbought conditions
  • Trading above the 200-day average of 12.22
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • RSI at 71.6 signals overbought conditions
  • P/E of 5.9 versus sector average of 31.1
  • Dividend yield of 8.14% looks stretched against payout coverage

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 5.9 versus sector average of 31.1
  • Dividend yield of 8.14% looks stretched against payout coverage
  • Negative profit margin of -41.9%

Key Metrics & Analysis

Financial Health

Revenue Growth-3.20%
Profit Margin-41.85%
P/E Ratio5.9
ROE-48.75%
ROA1.97%
Debt/Equity138.18
P/B Ratio0.8
Op. Cash Flow$196.1M
Free Cash Flow$437.2M
Industry P/E31.1

Technical Analysis

TrendNeutral
RSI71.6
Support$10.01
Resistance$14.26
MA 20$12.16
MA 50$11.09
MA 200$12.22
MACDBullish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair Value$18.15
Target Price$16.50
Upside/Downside15.79%
GradeUndervalued
TypeValue
Dividend Yield8.14%

Risk Assessment

Beta1.05
Volatility77.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.